Kyverna Therapeutics Inc
NASDAQ:KYTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its Industry Average (1.8), the stock would be worth $0 (100% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | $8.99 |
0%
|
| Industry Average | 1.8 | $0 |
-100%
|
| Country Average | 3 | $0 |
-100%
|
Forward EV/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
K
|
Kyverna Therapeutics Inc
NASDAQ:KYTX
|
542.9m USD | 0 | 0 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
301B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 351.6 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
101.6B ZAR | 8.9 | 10.5 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.7B USD | 0 | 38 243.7 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
56.3B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
38.3B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.5B EUR | 0.9 | 174.8 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.8B USD | 13.5 | -3 131.9 | |
| US |
R
|
Reddit Inc
NYSE:RDDT
|
30.6B USD | 11.8 | 53.8 |
Market Distribution
Other Multiples
Kyverna Therapeutics Inc
Glance View
Kyverna Therapeutics Inc is a US-based company operating in industry. The company is headquartered in Emeryville, California. The company went IPO on 2024-02-08. Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company. The firm is focused on developing cell therapies for patients suffering from autoimmune diseases. The firm's lead program, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor (CAR). The company intends to develop KYV-101 in two areas of autoimmune disease: rheumatology and neurology. Its initial rheumatology development focus is on lupus nephritis, and systemic sclerosis. The company is also actively developing an allogeneic, off-the-shelf approach to further broaden patient access. Its research-stage programs are focused on developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, and extend beyond CD19 CAR-T approaches, including regulatory T cells, or T-regs, and novel humanized CAR constructs developed by it for use in autoimmune diseases.
